“…However, these results may depend on the specific ClpP agonist studied. For example, ONC201 treatment increased apoptosis in mantle cell lymphoma, AML, pancreatic ductal adenocarcinoma, multiple myeloma, and ovarian cancer cell lines, whereas there have been no reports of significant increases in apoptosis after TR compound treatment [ 77 , 79 , 80 , 81 , 82 ]. ONC201 was previously reported to be both a ClpP agonist and a dopamine receptor D2 antagonist, while the TR compounds are selective ClpP agonists [ 33 , 35 , 83 ], which may explain these differences.…”